[go: up one dir, main page]

WO2003025019A8 - Anti-pdgf antibodies and methods for producing engineered antibodies - Google Patents

Anti-pdgf antibodies and methods for producing engineered antibodies

Info

Publication number
WO2003025019A8
WO2003025019A8 PCT/US2002/030086 US0230086W WO03025019A8 WO 2003025019 A8 WO2003025019 A8 WO 2003025019A8 US 0230086 W US0230086 W US 0230086W WO 03025019 A8 WO03025019 A8 WO 03025019A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
pdgf
producing engineered
engineered antibodies
Prior art date
Application number
PCT/US2002/030086
Other languages
French (fr)
Other versions
WO2003025019A9 (en
WO2003025019A1 (en
Inventor
Katherine S Bowdish
Shana Frederickson
Anke Kretz-Rommel
Original Assignee
Alexion Pharma Inc
Katherine S Bowdish
Shana Frederickson
Anke Kretz-Rommel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc, Katherine S Bowdish, Shana Frederickson, Anke Kretz-Rommel filed Critical Alexion Pharma Inc
Priority to JP2003528864A priority Critical patent/JP2005512962A/en
Priority to CA002460587A priority patent/CA2460587A1/en
Priority to EP02775937A priority patent/EP1436329A4/en
Publication of WO2003025019A1 publication Critical patent/WO2003025019A1/en
Publication of WO2003025019A8 publication Critical patent/WO2003025019A8/en
Publication of WO2003025019A9 publication Critical patent/WO2003025019A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods of making and selecting engineered antibodies and/or antibody fragments provide maximized binding affinity for a predetermined target and minimized immunogenicity when such antibodies are administered to a target species. Libraries containing variants of the engineered antibodies are also provided. In particularly useful embodiments, anti-PGDF antibodies and compositions are produced which are useful in the treatment of various cancers.
PCT/US2002/030086 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies WO2003025019A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003528864A JP2005512962A (en) 2001-09-20 2002-09-20 Method for producing anti-PDGF antibody and designed antibody
CA002460587A CA2460587A1 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies
EP02775937A EP1436329A4 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32353701P 2001-09-20 2001-09-20
US32354401P 2001-09-20 2001-09-20
US60/323,537 2001-09-20
US60/323,544 2001-09-20
US37999402P 2002-05-13 2002-05-13
US60/379,994 2002-05-13

Publications (3)

Publication Number Publication Date
WO2003025019A1 WO2003025019A1 (en) 2003-03-27
WO2003025019A8 true WO2003025019A8 (en) 2004-04-01
WO2003025019A9 WO2003025019A9 (en) 2004-05-06

Family

ID=27406282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/030086 WO2003025019A1 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Country Status (4)

Country Link
EP (1) EP1436329A4 (en)
JP (1) JP2005512962A (en)
CA (1) CA2460587A1 (en)
WO (1) WO2003025019A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4723810B2 (en) 2001-12-03 2011-07-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド Hybrid antibody
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
WO2003076568A2 (en) * 2002-02-11 2003-09-18 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
CA2523142A1 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
ES2388138T3 (en) * 2003-08-27 2012-10-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
AU2005227326B2 (en) * 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
JO3787B1 (en) 2012-03-15 2021-01-31 Janssen Biotech Inc Human anti-cd27 antibodies, methods, and uses
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN104508129A (en) * 2012-06-28 2015-04-08 分子伴侣公司 Designed ankyrin repeat proteins binding to platelet-derived growth factor
BR112015006929A2 (en) 2012-09-27 2017-07-04 Allergan Inc biodegradable drug delivery systems for sustained protein release
RU2720412C2 (en) 2013-03-14 2020-04-29 Аллерган, Инк. Sustained-release delivery composition and a method for stabilizing proteins in the manufacturing process
MY199027A (en) 2013-07-12 2023-10-10 Ophthotech Corp Method for treating or preventing ophthalmological conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
WO1999024059A1 (en) * 1997-11-07 1999-05-20 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
JP4460155B2 (en) * 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート Humanization of mouse antibodies

Also Published As

Publication number Publication date
WO2003025019A9 (en) 2004-05-06
EP1436329A1 (en) 2004-07-14
CA2460587A1 (en) 2003-03-27
JP2005512962A (en) 2005-05-12
WO2003025019A1 (en) 2003-03-27
EP1436329A4 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
WO2003025019A8 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
WO2003030833A3 (en) Angiopoietin-2 specific binding agents
WO2001070984A3 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2002088170A3 (en) Cripto blocking antibodies and uses thereof
IL161016A (en) Polypeptides capable of binding to ang-2
AU3117201A (en) Methods and compositions for generating human monoclonal antibodies
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
WO2002083849A3 (en) Vascular endothelial growth factor 2
WO2003042247A3 (en) Modified anti-tnf alpha antibody
EP1693384A3 (en) Functional immunoglobulins against human serum albumin, fragments thereof, library thereof and methods of production thereof
WO2002099084A3 (en) Composite binding polypeptides
WO2002072826A3 (en) Neurotrophic factors
AU2002303214A1 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
WO2005030793A3 (en) Antibodies which bind human cxcr3
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2001287040A1 (en) Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
IL175646A0 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
AU2002315066A1 (en) Methods for making antibody fragments and compositions resulting therefrom
WO2002097097A3 (en) Compositions and methods of increasing stress tolerance in plants
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2002059322A3 (en) Compositions and methods relating to the daptomycin biosynthetic gene cluster
WO2003014297A3 (en) Compositions and methods relating to the daptomycin biosynthetic gene cluster

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002341785

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002775937

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2460587

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003528864

Country of ref document: JP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 13/2003 UNDER (72, 75) THE NATIONALITY AND RESIDENCE OF "KRETZROMMEL, ANKE" SHOULD READ "[CH/US]"

COP Corrected version of pamphlet

Free format text: PAGES 1/40-40/40, DRAWINGS, REPLACED BY NEW PAGES 1/44-44/44; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2002775937

Country of ref document: EP